{"id":"W2804990894","doi":"10.3324/haematol.2017.171249","title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study","year":2018,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Pfizer","keywords":"Bosutinib; Medicine; Cumulative incidence; Internal medicine; Nausea; Myeloid leukemia; Adverse effect; Imatinib; Gastroenterology; Rash; Mucositis; Oncology; Dasatinib; Surgery; Toxicity; Cohort","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003004331,0.0008247996,0.001383113,0.0003035051,0.0003664535,0.0008055868,0.0004528489,0.0008427294,0.0008912121],"category_scores_gemma":[0.001066087,0.0002422361,0.001236492,0.0002877879,0.000401922,0.0005380212,0.00024196,0.001512103,0.0003249571],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006511565,"about_ca_system_score_gemma":0.0007030154,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007332636,"about_ca_topic_score_gemma":0.001267321,"domain_scores_codex":[0.9993599,0.0002180672,0.00005195424,0.00009688141,0.000127953,0.0001452057],"domain_scores_gemma":[0.9987693,0.0001459945,0.0004175524,0.0000938903,0.0001403144,0.0004328884],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4274169,0.06843876,0.1677295,0.0007729593,0.003812361,0.001025589,0.0006743592,0.005485903,0.1076739,0.0002213757,0.00531328,0.2114351],"study_design_scores_gemma":[0.06915899,0.5904337,0.3213701,0.00003960598,0.001443571,0.0008650984,0.00009918909,0.001973382,0.01040665,0.00007906686,0.004075587,0.00005511998],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969051,0.001462455,0.0003173464,0.00008889406,0.00002535064,0.0002391745,0.0004472222,0.00002362759,0.000490815],"genre_scores_gemma":[0.99692,0.0004509708,0.0002093133,0.0002153431,0.00005600592,0.0001744803,0.00143588,0.000006341593,0.0005317152],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003004331,"threshold_uncertainty_score":0.01588857,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03689671586753953,"score_gpt":0.344653472804586,"score_spread":0.3077567569370465,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}